Navigation Links
Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
Date:3/13/2008

products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the ability of Boston Scientific Corporation to successfully manufacture, market and sell their paclitaxel-eluting coronary stent products; the continued availability of capital to finance our activities; our ability to achieve the financial benefits expected as a result of the acquisition of American Medical Instruments Holdings, Inc. ("AMI"); and any other factors referenced in our annual information form and other filings with the applicable Canadian securities regulatory authorities or the SEC. Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

(TM) Option is a trademark of Rex Medical, LP, used under license by

Angiotech. EnSnare is a trademark of Angiotech.

CONTACT: Angiotech Contact: Deirdre Neary, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
2. Angiotech announces results for the fourth quarter ended December 31, 2007
3. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
5. Angiotech and Symphony Medical Announce Licensing Agreement
6. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
7. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
8. Angiotech to participate in RBC 2007 Healthcare Conference
9. Angiotech to participate in Bank of America 2007 Credit Conference
10. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
11. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today ... a presentation to investors on Tuesday, July 29, ...  The presentation will include an overview of Asterias, ... the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least ...
(Date:7/24/2014)... Quantum computers have yet to materialise. Yet, scientists ... making such computers faster. One such approach relies ... controlled by applying an electric field. A new ... coherently coupled quantum dots (TQDs) with electrical impulses ... for example, should TQDs be used as quantum ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Provide Proprietary Protein and Small Molecule Products for ... Stem (iPS) CellsLA JOLLA, Calif. and BOSTON, April ... and Stemgent, Inc. ... one-of-a-kind program to provide pharmaceutical and biotechnology companies ...
... 23 /PRNewswire-Asia/ -- Lotus Scarless Hair Transplantation,(International) Medical ... flagship transplant center on the prestigious Chang,an Avenue ... the first U.S. specialized,medical and plastics institution for ... With a floor area of 1,000 square ...
... drug delivery - , , MADISON, ... Roche Madison Inc. officially opened the doors to ... labs at the University of Wisconsin ... RNA Therapeutics group within Roche, the group,s research ...
Cached Biology Technology:Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 2Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 3Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 4Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijing's Prestigious Chang'An Avenue 2Roche Madison Moves to New Facility 2Roche Madison Moves to New Facility 3
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, ... devices, has cut emergency room wait times by an ... (UCSD) Medical Center, according to a recent study published ... Departments are using the suite to access data from ... defibrillators. "Using Geneva,s technology platform we have ...
(Date:7/24/2014)... for food or commercial food sale, has been heavily ... of many species of primates and other mammals. ... of the species being consumed are birds, particularly large ... the meat made available for sale but the meat ... and brought to villages for consumption, we noted a ...
(Date:7/24/2014)... different effects on different species of fish, according ... Bristol and Exeter which tested fish anti-predator behaviour. ... flying seagull predator model when exposed to additional ... minnows. , Lead author Dr Irene Voellmy ... levels in many aquatic environments have increased substantially ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... the eye where faces are concerned. With colleagues ... investigating the process of facial recognition, seeking to understand the ... when one person looks at another. His studies ... condition long known as prosopagnosia. Duchaine is trying to understand ...
... release is also available in Chinese on ... sun comes up, the ocean ground is radically cleaned. As ... into the water, the microalgae "Nitzschia cf pellucida" start their ... few micrometers, wrap themselves and their surroundings in a highly ...
... first of its kind book provides a practical guide ... and natural resources sciences. ,Analysis of Generalized Linear Mixed ... being released world-wide at an important time of change ... the design and analysis of mixed models for non-normally ...
Cached Biology News:Just another pretty face: Dartmouth professor investigates neural basis of prosopagnosia 2Just another pretty face: Dartmouth professor investigates neural basis of prosopagnosia 3Poisonous morning hygiene 2
Lipid Phosphate Phosphohydrolase 2...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: